|

货币单位:美元(USD)

SomaLogic, Inc. (slgc)

实时(?):

盘后(?):

读取中...

-- (--%)

开盘价:--	最高价:--	最低价:--	52周最高价:--	52周最低价:--
成交量:--	平均成交量:--	市值:--	市盈率:--	预期市盈率:--
每股收益:--	贝塔系数:--	股息:--	收益率:--	总股本:--

提示:交易结束

Michael Egholm	Michael Egholm was the founder of Danaher Corp. (founded in 2017) where he held the title of Chief Technology Officer-Danaher Life Sciences from 2017 to 2021. He is currently the President, Chief Executive Officer & Director at Standard BioTools, Inc. (since 2022) and the President, CEO, Secretary, Treasurer & Director at SomaLogic, Inc. (since 2024). He is also a Director at Abbratech, Inc. and a Member of the Royal Danish Academy of Sciences & Letters. In his former positions, he served as an Independent Director at IsoPlexis Corp. (2018-2022), President-Biopharmaceuticals at Pall Corp. (2014-2017), Vice President-Research at Molecular Staging, Inc., and Chief Technology Officer at 454 Life Sciences Corp. He also held the position of Chief Technology Officer at Roche Applied Science from 2008 to 2010. Dr. Egholm obtained a doctorate degree from the University of Copenhagen.

Michael Egholm

Michael Egholm was the founder of Danaher Corp. (founded in 2017) where he held the title of Chief Technology Officer-Danaher Life Sciences from 2017 to 2021. He is currently the President, Chief Executive Officer & Director at Standard BioTools, Inc. (since 2022) and the President, CEO, Secretary, Treasurer & Director at SomaLogic, Inc. (since 2024). He is also a Director at Abbratech, Inc. and a Member of the Royal Danish Academy of Sciences & Letters. In his former positions, he served as an Independent Director at IsoPlexis Corp. (2018-2022), President-Biopharmaceuticals at Pall Corp. (2014-2017), Vice President-Research at Molecular Staging, Inc., and Chief Technology Officer at 454 Life Sciences Corp. He also held the position of Chief Technology Officer at Roche Applied Science from 2008 to 2010. Dr. Egholm obtained a doctorate degree from the University of Copenhagen.